button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus interferon alpha
Ipilimumab (10 mg/kg) vs. interferon alpha 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		-NaN [NaN; NaN] /10000
0/0 vs. 0/0
ipilimumab alone vs. interferon alpha 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		-NaN [NaN; NaN] /10000
0/0 vs. 0/0
versus placebo
Ipilimumab (10 mg/kg) vs. placebo 1 -1085 [-1703; -468] /10000
162/475 vs. 214/476		--1250 [-1877; -623] /10000
234/475 vs. 294/476

mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus gp100
ipilimumab alone vs. gp100 1 -1451 [-2379; -522] /10000
100/137 vs. 119/136		--
ipilimumab plus gp100 vs. gp100 1 -1157 [-1852; -462] /10000
306/403 vs. 119/136		--
versus ipilimumab alone
Ipilimumab (10 mg/kg) vs. ipilimumab alone 1 -529 [-1162; 104] /10000
262/365 vs. 279/362		-130 [-556; 296] /10000
328/365 vs. 330/362		-
ipilimumab plus gp100 vs. ipilimumab alone 1 294 [-559; 1146] /10000
306/403 vs. 100/137		--
versus placebo plus SoC
ipilimumab plus SoC vs. placebo plus SoC 1 -811 [-1473; -149] /10000
196/250 vs. 218/252		-729 [-1354; -105] /10000
203/250 vs. 223/252		-

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons